ClinicalTrials.gg
Not yet recruitingNCT05997459Updated Aug 18, 2023

A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

A Phase 2 interventional study of Pemigatinib in Locally Advanced Unresectable Gastric Cancer, sponsored by Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stomach Neoplasms by Sun Yat-sen University — 6 open to participants now, 7 under way, 2 of them phase 3. Stomach Neoplasms · Sun Yat-sen University.

Planned enrollment
22nd of 23
23 · median 110
Started
2023
with 3 others
Phase 2
12 of 29
3 open now
Registered
27th of 29
by date

Among the 29 studies in Stomach Neoplasms by Sun Yat-sen University, this one is the 22nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2023, is one of 12 in phase 2, and was the 27th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 29 studies in Stomach Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stomach Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

purpose of research: fundamental purpose:

  • To evaluate the effectiveness of pemitinib in patients with advanced gastric cancer who have failed standard therapy with fibroblast growth factor receptor 1-3 (FGFR1-3) variant (including but not limited to FGFR1-3 amplification, rearrangement / fusion, mutation, etc.).

Secondary purpose:

  • To evaluate the safety and tolerability of pemitinib in patients with advanced gastric cancer who have previously failed standard therapy with the FGFR1-3 variant: including incidence of adverse events (AEs) and serious adverse events (SAEs) and association with therapy. Incidence of treatment-related AEs / SAEs.
  • Exploring efficacy and safety in subjects with different FGFR variant types.

The end of the study:

Main end point:

  • The primary endpoint of the study was the 6-month PFS rate (progression-free survival, defined as first dose to disease progression [PD] or death).

Secondary end point:

  • Objective response rate (defined as the proportion of subjects achieving complete response (CR) or partial response (PR) by RECIST1.1 criteria).

Duration of response (DOR, defined as the time from first CR or PR to PD, is used only for subjects with an objective response).

  • Disease control rate (DCR, defined as the proportion of subjects with CR + PR + stable disease stable [SD]).
  • Overall survival (OS, defined as the time of first dose to death from any cause).
  • Safety and tolerability: Grade evaluation for assessing the severity of adverse events according to NCI CTCAE (version 5.0), including:

    1. Incidence, severity, and association of all AEs, TRAEs, SAEs, and the study drug;
    2. Number and proportion of subjects stopping treatment due to the above adverse events;
    3. Study changes in vital signs, physical examination findings, and laboratory results before, during and after treatment.
  • To describe the efficacy and safety in subjects with different FGFR gene variant types.
Read the detailed description

research design: This study is a prospective, single-arm, phase II clinical study. Patients with advanced gastric cancer who had failed standard treatment with FGFR1-3 variant, were included in the study by meeting the inclusion criteria after completing the informed consent. Patients will receive pemitinib 13.5 mg once daily (QD) orally on a 2-week dose / 1-week withdrawal regimen. Subjects will continue treatment until disease progression or intolerable toxicity. Clinical tumor imaging evaluation per RECIST v1.1, every 6 weeks (± 7 days) and every 9 weeks (± 7 days) after 48 weeks. Safety assessment was performed using NCI-CTCAE 5.0.

Pemitinib, dose and mode of administration:

Pemitinib will be treated as a 2 week / 1 week withdrawal regimen, 1 dose, 13.5mg, QD, 21 day cycle. Subjects should be on pometitinib at a fixed time per day to avoid inconsistent effects on plasma concentration.

Sample size and statistical methods:

  1. In this study, using the 6-month PFS rate as the primary endpoint, Calculted using the confidence interval method of Kapian-Meier estimation, Based on the historical data, The 6-month PFS rate of second-line chemotherapy in subjects with previous first-line treatment was approximately 20% (RAINBOW study, BRIGHTER Study), The 6-month PFS rate in subjects with previous second-line or more treatment was approximately 10% (Attraction-2 study), It is estimated that about 20% of the second-line and above treated subjects will be included in this study, The overall 6-month PFS rate was about 18%, Assuming that the 6-month PFS rate could be improved to 36%, Using the test level as one-sided α =0.1, ß=0.20, After follow-up for at least 6 months, With 80% confidence be observed with a 90% confidence interval lower bound greater than 18%, In total, 23 subjects will need to be enrolled.
  2. Statistical analysis method: Continuous variables were described by mean, standard deviation, median, minimum and maximum values, and categorical variables were described by frequency and percentage. The proportion of subjects with the ORR and DCR and their 95% CI were estimated. Median PFS, DOR, and OS were estimated using Kaplan-Meier.
03

Conditions studied

  • Locally Advanced Unresectable Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Main selection criteria:

Written was signed prior to the implementation of any trial-related process;

  1. Age: 18 years old;
  2. Advanced gastric cancer was confirmed histologically or cytologically;
  3. At least one as per version v1.1;
  4. Histology confirmed the presence of the FGFR1-3 variant, including but not limited to amplification, mutation, fusion / rearrangement;
  5. Patients who are tested negative for HER 2 by immunohistochemistry (IHC), or by immunohistochemistry (ICH) and in situ hybridization (ISH);
  6. Progressive disease after standard treatment;
  7. No previous small molecule multitarget inhibitors containing FGFR pathway (including but not limited to allotinib, lemavatinib, sorafenib, apatinib, etc.);
  8. The physical fitness status is 0-1;
  9. Expected survival time of> 3 months;

Exclusion criteria

Exclusion Criteria:

  • Written was signed prior to the implementation of any trial-related process;
  1. Age: 18 years old;
  2. Advanced gastric cancer was confirmed histologically or cytologically;
  3. At least one as per version v1.1;
  4. Histology confirmed the presence of the FGFR1-3 variant, including but not limited to amplification, mutation, fusion / rearrangement;
  5. Patients who are tested negative for HER 2 by immunohistochemistry (IHC), or by immunohistochemistry (ICH) and in situ hybridization (ISH);
  6. Progressive disease after standard treatment;
  7. No previous small molecule multitarget inhibitors containing FGFR pathway (including but not limited to allotinib, lemavatinib, sorafenib, apatinib, etc.);
  8. The physical fitness status is 0-1;
  9. Expected survival time of> 3 months;
  10. For icient organ function for the following laboratory indicators:

    1. In the absence of granulocyte colony-stimulating factor for the last 14 days (ANC)≥1.5x109/L;
    2. In the last 14 days without blood transfusion, 100109/L;
    3. > 9 g/dL without blood transfusion or erythropoietin in the last 14 days;
    4. Total 1.5 (ULN); or total bilirubin> ULN but direct bilirubin ULN;
    5. Asparpartate aminotransferase (), alanine transaminotransferase (ALT) at 2.5 ULN (ALT or AST 5 ULN is allowed in patients with liver );
    6. Blood creatinine of 1.5 ULN and (calculated using the Cockcroft-Gault formula) of 50 ml / min;
    7. The coagulation function is good, defined as the (INR) or prothrombin time (PT) 1.5 times ULN; if the subject is undergoing anticoagulant therapy, as long as the PT is within the proposed range of the anticoagulant
  11. For female subjects of childbearing age, a urine or serum pregnancy test within 3 days prior to the first dose of study drug (cycle 1 Day 1, was negative). If the urine pregnancy test results cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing women were defined as at least 1 year after menopause, or had undergone surgical sterilization or hysterectomy;
  12. If there is a risk of conception, all subjects (either male or female) should have an annual failure rate below 1% for the entire treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy drug).

Main exclusion criteria:

  1. Other malignant diseases other than digestive tract tumors diagnosed within 5 years before the first dose (excluding radical skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or radical resection);
  2. Previous selective FGFR inhibitor therapy;
  3. Have received any other study drug or attended an interventional clinical investigator within 28 days prior to the first dose; or had received antitumor treatment (including herbal medicine with anti-tumor indications) within 28 days prior to the initial dose of the study drug;
  4. Not yet adequate recovery from toxicity and / or complications due to any intervention (i. e., grade 1 or at baseline, excluding fatigue or alopecia);
  5. Known to of symptomatic and / or cancerous meningitis. The previously treated subjects could participate in the trial if stable (no evidence of radiographic progression within at least 4 weeks before the first dose of trial treatment), repeat imaging confirmed no evidence of new brain metastases or enlargement of lesions, and no treatment was required at least 14 days before the first dose. This exception does not include cancerous meningitis, which should be ruled out regardless of its stable clinical status;
  6. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation;
  7. The following laboratory parameters are abnormal:

    1. Serum phosphates> ULN;
    2. Serum calcium exceeds the normal range, or when serum albumin is beyond the normal range, the corrected calcium concentration of serum albumin is beyond the normal range;
    3. Potassium level \<lower normal; potassium level can be corrected by supplements at screening.
  8. Known history of (HIV) infection or confirmed positive immune test results;
  9. Severe infection with active period or poor clinical control;
  10. Thorachydrate, ascites or pericardial effusion with obvious clinical symptoms and requiring drainage;
  11. Patients infected with acute or chronic active or , hepatitis B virus (HBV) DNA> 2000 IU / ml or 104Copy / ml; hepatitis C virus (HCV) RNA> 103Copy / ml; hepatitis B surface antigen (HbsAg) was positive with anti-HCV antibody. After the nucleotide antiviral treatment is lower than the above standards, they can be enrolled;
  12. or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months before the first dose, grade III / IV congestive heart failure, and uncontrolled cardiac disorders (allowing pacemaker wear or subjects with atrial fibrillation with good heart rate control);
  13. With change or medical history considered clinically significant by the investigator; screen interval> 480 ms, for subjects with indoor block (QRS interval> 120 ms), use JTc interval instead of QTc interval (if JTc is used instead of QTc, JTc must be 340 ms);
  14. Uncontrolled hypertension, systolic blood pressure> 160 mmHg or diastolic blood pressure> 100 mmHg after optimal medical treatment, a history of hypertensive crisis or hypertensive encephalopathy;

Main exclusion criteria:

  1. Other malignant diseases other than digestive tract tumors diagnosed within 5 years before the first dose (excluding radical skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or radical resection);
  2. Previous selective FGFR inhibitor therapy;
  3. Have received any other study drug or attended an interventional clinical investigator within 28 days prior to the first dose; or had received antitumor treatment (including herbal medicine with anti-tumor indications) within 28 days prior to the initial dose of the study drug;
  4. Not yet adequate recovery from toxicity and / or complications due to any intervention (i. e., grade 1 or at baseline, excluding fatigue or alopecia);
  5. Known to of symptomatic CNS metastases and / or cancerous meningitis. The previously treated subjects could participate in the trial if stable (no evidence of radiographic progression within at least 4 weeks before the first dose of trial treatment), repeat imaging confirmed no evidence of new brain metastases or enlargement of lesions, and no steroid treatment was required at least 14 days before the first dose. This exception does not include cancerous meningitis, which should be ruled out regardless of its stable clinical status;
  6. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
  7. The following laboratory parameters are abnormal:

    1. Serum phosphates> ULN;
    2. Serum calcium exceeds the normal range, or when serum albumin is beyond the normal range, the corrected calcium concentration of serum albumin is beyond the normal range;
    3. Potassium level \<lower normal; potassium level can be corrected by supplements at screening.
  8. Known history of human immunodeficiency virus (HIV) infection or confirmed positive immune test results;
  9. Severe infection with active period or poor clinical control;
  10. Thorachydrate, ascites or pericardial effusion with obvious clinical symptoms and requiring drainage;
  11. Patients infected with acute or chronic active hepatitis B or hepatitis C, hepatitis B virus (HBV) DNA> 2000 IU / ml or 104Copy / ml; hepatitis C virus (HCV) RNA> 103Copy / ml; hepatitis B surface antigen (HbsAg) was positive with anti-HCV antibody. After the nucleotide antiviral treatment is lower than the above standards, they can be enrolled;
  12. Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months before the first dose, New York Heart Association grade III / IV congestive heart failure, and uncontrolled cardiac disorders (allowing pacemaker wear or subjects with atrial fibrillation with good heart rate control);
  13. With ECG change or medical history considered clinically significant by the investigator; screen QTcF interval> 480 ms, for subjects with indoor block (QRS interval> 120 ms), use JTc interval instead of QTc interval (if JTc is used instead of QTc, JTc must be 340 ms);
  14. Uncontrolled hypertension, systolic blood pressure> 160 mmHg or diastolic blood pressure> 100 mmHg after optimal medical treatment, a history of hypertensive crisis or hypertensive encephalopathy;
  15. Hepatic encephalopathy, hepatorenal syndrome or B or more severe cirrhosis.
  16. A major surgical procedure (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to the first dose of study treatment or is expected to require major surgery during the study treatment;
  17. Complications of toxicity and / or major surgery have not recovered sufficiently before starting treatment;
  18. Women in pregnancy or lactating, or subjects expected to be pregnant or born during the study from the screening visit to completion of the safety follow-up visit (male subjects to 90 days after the last dose);
  19. Received radiotherapy within 4 weeks before the first dose of the study drug. The subject with radiotherapy-related toxicity must have fully recovered and not require corticosteroid therapy, confirming the exclusion of radiation pneumonia. For palliative radiotherapy for non-CNS disease, a 2-week is allowed;
  20. A history of systemic electrolyte metabolic imbalance with calcium and phosphorus metabolism disorders or soft tissue ectopic calcification (except for the calcification of skin, kidney, tendon, or vascular soft tissue without systemic electrolyte metabolic imbalance caused by injury, disease, and advanced age);
  21. Clinically significant corneal or retinal disease confirmed by ophthalmic examination;
  22. Any potent inhibitor (see Appendix A) or inducer has been used for 14 days or 5 half-lives (whichever shorter) prior to the first dose of the study drug. Exogenous use of ketoconazole is allowed;
  23. Known allergic reactions to peometinib or peometinib study drug ;
  24. Failure or unwillingness to swallow peimitinib or significant digestive diseases that may interfere with absorption, metabolism or excretion;
  25. The subject had a history of vitamin D deficiency and needed an excessive amount of vitamin D supplementation (except for vitamin D dietary supplements);
  26. Other acute or chronic illness, mental illness, or abnormal laboratory tests that may increase the risk of study participation or study drug administration or interfere with the interpretation of study results and identify the patient as ineligible for the study in the discretion of the investigator.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    experimental group

    Drug: Pemigatinib

Interventions

  • Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W

06

What researchers measure

Primary outcomes

  1. PFS

    to evaluate the efficacy of pemitinib in patients with advanced gastric cancer who have previously failed standard therapy with FGFR1-3 variants

    Time frame: 6-month PFS

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Dec 2024, 16 months later.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 16 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Aug 18, 2023
StartEst.
Aug 25, 2023
Primary completionEst.
Dec 30, 2024
CompletionEst.
Mar 30, 2025
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05997459
Responsible party
Dong sheng Zhang (chief physician, Sun Yat-sen University) — Principal investigator
First posted
Aug 18, 2023
Start date
Aug 25, 2023 (estimated)
Primary completion
Dec 30, 2024 (estimated)
Completion
Mar 30, 2025 (estimated)
Last update
Aug 18, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion